← Back to Episodes
PODCAST

Your Dentist Might Know Something About Your Bones Before Your Doctor Does

October 5, 2026·9:12·Episode 138

Quick Summary

This episode covers three research papers relevant to postmenopausal health: a Chinese study on whether a DNA-based cervical screening test performs differently after menopause, a clarification on a vitamin D drug used for bone thinning, and a cross-sectional study on whether dental imaging can flag low bone density before a formal bone scan is ever ordered.

Your Dentist Might Know Something About Your Bones Before Your Doctor Does

0:000:00

Key Takeaways

  • ✦A DNA methylation test used for cervical screening (PAX1/JAM3) appears to perform differently in postmenopausal women than in premenopausal women — which matters for how results should be read and acted on.
  • ✦Eldecalcitol, a stronger vitamin D drug used in some Asian countries for postmenopausal bone thinning, is not the same as the vitamin D supplement on your shelf — the distinction matters when reading research about it.
  • ✦A type of dental X-ray called a CBCT scan can estimate bone density in the jaw, and this study found meaningful overlap with formal bone density scores (DEXA T-scores) — a possible early-detection signal that most dental visits don't flag.
  • ✦The CBCT-bone density connection is cross-sectional and preliminary — it shows an association, not a proven screening tool. Researchers are not saying "skip the DEXA."
  • ✦All three studies are observational or retrospective, conducted primarily in Asian populations, and need replication before changing clinical practice in other groups.

Episode Script

Thanks Toni. We've got some genuinely interesting research today — nothing earth-shattering, but the kind of stuff worth knowing about.

All three papers that landed on my radar this week are focused on postmenopausal women specifically, which I always appreciate, because a lot of research just lumps women together across age groups and then acts surprised when the results are messy. Let's get into it.


The first one is about cervical screening, and I want to spend a minute explaining what this test actually is, because it's not the standard Pap smear most of us are familiar with.

Researchers in China published a study looking at something called PAX1 and JAM3 methylation testing. Methylation is a process your cells use to turn genes on or off. In certain cervical cells that are becoming precancerous or cancerous, specific genes get chemically switched off — and these tests detect that switch. Think of it as a molecular fingerprint that says "something is changing here" even before the cell looks visibly abnormal under a microscope.

This kind of testing is already used in some parts of the world as a cervical screening tool, often alongside or after an HPV test comes back positive. The question this study was asking: does the test perform the same way in women who have already gone through menopause, compared to women who haven't?

The short answer from this retrospective study — meaning they looked backward at records from patients who already had testing done — is that the test behaves somewhat differently depending on menopausal status. The sensitivity and specificity numbers shifted. Those terms just mean: how good is the test at catching the problem when it's there, and how good is it at not raising a false alarm when there's nothing there.

Why does menopause matter here? Because after menopause, the cervical tissue itself changes. The cells thin out, the pH shifts, and the overall environment is different. A test that's been calibrated on mostly premenopausal women may need its cutoffs adjusted to work as reliably in a postmenopausal population.

My read on this: it's a real and important question. If these tests get rolled out more widely — and there's been growing interest in them as a way to triage HPV-positive results — then developers and labs need to make sure the performance data actually includes postmenopausal women, not just assumes they're the same. That's a basic quality standard that doesn't always get applied.

The study is retrospective, it's from a single country, and the patient population may not map directly to women in other parts of the world. So this doesn't change anything about your own screening decisions. But for anyone following where cervical screening technology is going, this is a piece of the picture that matters.


The second paper is a reply letter — which sounds like a minor thing, but reply letters in medical journals can actually be clarifying in useful ways.

The original study looked at eldecalcitol combined with calcium for postmenopausal bone thinning. Eldecalcitol is a drug used primarily in Japan that's a more potent synthetic version of vitamin D. Not the supplement. Not the vitamin D3 capsule you might be taking. A pharmaceutical compound that your body handles differently and that's not available in most Western countries.

Someone wrote in to comment on the original study — raising a methodological point — and the authors responded. The back-and-forth touches on how you measure outcomes in bone-thinning research, and what counts as a meaningful improvement versus statistical noise.

I'm not going to get deep into the mechanics of the dispute, because it's genuinely technical and the details would take longer to explain than the payoff warrants. What I do want to flag is the bigger-picture thing this reminded me of.

Bone thinning after menopause is a real problem that gets both underdiagnosed and, in some corners of the wellness world, wildly misrepresented. The underdiagnosis side: women often don't get their first bone density scan until they've already had a fracture, which is too late to call it prevention. The overpromise side: you can find plenty of influencers and supplement brands telling you that a specific calcium-magnesium-vitamin K2 stack will "rebuild" your bones, with very little evidence behind that specific combination at those specific doses.

Eldecalcitol is at least a real pharmaceutical compound with real clinical trials behind it. The fact that researchers are arguing in the pages of a journal about the right way to interpret those trials is actually the system working as intended. That's peer review doing its job.

If you're outside Japan, this drug isn't on your radar for a reason. But the underlying question — what actually moves the needle on bone density after menopause, and how do we measure that reliably — is very much alive, and the evidence is genuinely more complicated than "take your calcium."


The third study is the one I find most worth talking about, and it's about dental imaging.

Researchers looked at whether a specific type of dental X-ray — called a cone beam CT, or CBCT — could give useful information about bone density beyond just the jaw. The CBCT scan is already common in dental practices for things like planning implants or evaluating jaw structure. It produces a detailed three-dimensional image, and it captures gray-scale values that correspond to how dense the bone is in the imaging area.

What these researchers found, in a cross-sectional study of postmenopausal women, is that the gray values and a related measure called fractal dimension — which captures how complex or irregular the bone structure looks — showed meaningful overlap with DEXA T-scores. A DEXA scan is the standard bone density test, the one that produces the T-score your doctor uses to determine if you have osteopenia or osteoporosis. And T-scores from different sites in the body — hip, spine — showed different patterns of correlation with the jaw measurements. Hence the "site-specific" in the title.

Cross-sectional means they took one snapshot in time across a group of women — they didn't follow anyone forward, and they can't say that one measurement predicts the other in a clinical sense. Association is not the same as a validated screening tool. The researchers themselves are not saying "replace the DEXA with dental imaging." That would be a leap the data doesn't support.

But here's what I think is genuinely worth sitting with: most postmenopausal women are not getting DEXA scans on schedule. Screening guidelines say you should typically get your first one at 65, or earlier if you have risk factors. In practice, a lot of women fall through the cracks. They're not getting referred, or they don't know to ask, or it's not covered smoothly by their insurance.

Meanwhile, many of those same women are going to the dentist. Getting jaw X-rays. Sitting in that chair once or twice a year.

The question this study is nudging us toward — even if it can't answer it yet — is whether that dental visit could become an early signal. Not a diagnosis. Not a replacement for a bone scan. But a prompt. A reason for a dentist to say, "Hey, based on what I'm seeing here, have you talked to your doctor about getting a bone density check?"

That handoff doesn't require the dental X-ray to be a perfect bone density predictor. It just requires enough of a signal to justify a conversation that often isn't happening.

The study needs to be replicated in larger and more diverse populations before anyone should change clinical practice based on it. It was conducted in a specific region with a specific patient group, and bone density and its relationship to jaw structure may vary. But as a proof-of-concept that there's information hiding in imaging most women already have access to — that's worth watching.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.